Edition:
United Kingdom

SCYNEXIS Inc (SCYX.OQ)

SCYX.OQ on NASDAQ Stock Exchange Global Market

1.94USD
20 Nov 2017
Change (% chg)

$0.06 (+3.19%)
Prev Close
$1.88
Open
$1.89
Day's High
$1.95
Day's Low
$1.89
Volume
13,406
Avg. Vol
30,548
52-wk High
$4.00
52-wk Low
$1.53

Latest Key Developments (Source: Significant Developments)

Scynexis reports third quarter 2017 financial results
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Scynexis Inc :Scynexis reports third quarter 2017 financial results and provides company update.Q3 loss per share $0.31.Q3 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.  Full Article

SCYNEXIS says achieves new development milestones for SCY-078
Tuesday, 13 Dec 2016 

SCYNEXIS Inc : Pending discussions with FDA, plan to test in upcoming clinical trials of SCY-078 . Scynexis achieves new development milestones reinforcing versatility of SCY-078 in treating serious fungal infections .SCY-078 toxicology program was expanded to include three-month oral dose studies in two species.  Full Article

Scynexis enters into loan and security agreement with Solar Capital
Wednesday, 5 Oct 2016 

Scynexis Inc : On September 30, 2016, Co entered into loan and security agreement with Solar Capital Ltd. - SEC filing .Solar providing Co with 48-month secured term loan of $15 million and all principal and accrued interest on term loan due on Sept 30, 2020.  Full Article

Scynexis announces sale of Cyclophilin inhibitor assets to Cypralis Ltd
Wednesday, 13 Jul 2016 

Scynexis Inc : Scynexis announces sale of Cyclophilin inhibitor assets to Cypralis Ltd .Financial terms of agreement were not disclosed..  Full Article

Scynexis says CEO Marco Taglietti purchased 100,000 shares - SEC filing
Tuesday, 28 Jun 2016 

Scynexis Inc : CEO Marco Taglietti reports purchase of 100,000 shares of co's common stock on June 24 at $2.39 per share - SEC filing Source: (http://1.usa.gov/29bI1Ch ) Further company coverage: [SCYX.O] (Bengaluru Newsroom: +1 646 223 8780).  Full Article

Scynexis director Guy Macdonald reports purchase of 40,000 shares - SEC filing
Tuesday, 28 Jun 2016 

Scynexis Inc : Director Guy Macdonald reports purchase of 40,000 shares of co's common stock on June 24 at $2.39 per share - SEC filing Source: (http://1.usa.gov/290khhU ) Further company coverage: [SCYX.O] (Bengaluru Newsroom: +1 646 223 8780).  Full Article

Scynexis receives orphan drug designation for SCY-078
Friday, 13 May 2016 

Scynexis Inc : Scynexis Inc Receives orphan drug designation for SCY-078 for the treatment of invasive Candida infections .Expects top line data from two ongoing phase 2 studies of SCY-078's oral formulation in June and July 2016.  Full Article

Scynexis reports Q1 loss of $0.52 per share
Monday, 9 May 2016 

Scynexis Inc : Qtrly revenue $64,000 versus $65,000 . Q1 earnings per share view $-0.63, revenue view $100000.00 -- Thomson Reuters I/B/E/S . Scynexis, inc. Reports first quarter 2016 financial results and provides company update . Q1 loss per share $0.52 .Q1 earnings per share view $-0.63 -- Thomson Reuters I/B/E/S.  Full Article

Scynexis Inc receives FDA Fast Track and QIDP Designations for Intravenous Formulation of SCY-078
Thursday, 28 Jan 2016 

Scynexis Inc:Announced that the U.S. Food and Drug Administration (FDA) has granted both Fast Track and Qualified Infectious Disease Product (QIDP) designations for the intravenous (IV) formulation of SCY-078.SCYNEXIS' novel antifungal product, for the indications of invasive candidiasis (including candidemia) and invasive aspergillosis.  Full Article

BRIEF-Scynexis reports third quarter 2017 financial results

* Scynexis reports third quarter 2017 financial results and provides company update